Top

Current Oncology Reports

Published in:

Open Access 01-08-2021 | Ovarian Cancer | Gynecologic Cancers (J Brown and RW Naumann, Section Editors)

Frontline Maintenance Treatment for Ovarian Cancer

Authors: Osnat Elyashiv, Yien Ning Sophia Wong, Jonathan A. Ledermann

Published in: Current Oncology Reports | Issue 8/2021

Abstract

Purpose of Review

Advanced epithelial ovarian cancer remains the most lethal gynaecological cancer. Most patients with advanced disease will relapse within 3 years after primary treatment with surgery and chemotherapy. Recurrences become increasing difficult to treat due to the emergence of drug resistance and 5-year survival has changed little over the last decade. Maintenance treatment, here defined as treatment given beyond primary chemotherapy, can both consolidate the response and prolong the control of disease which is an approach to improve survival.

Recent Findings

Here we review maintenance strategies such as targeting angiogenesis, interference of DNA repair through inhibition of PARP, combinations of targeting agents, and immunotherapy and hormonal therapy.

Summary

Much has been learnt from the success and challenges of these treatments that have in the last few years which led to significant reduction in disease recurrence, changed the guidelines for treatment, and established a new paradigm for the treatment of ovarian cancer.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Kurman RJ. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann Oncol. 2013;24 Suppl 10:x16–21. https://doi.org/10.1093/annonc/mdt463.CrossRefPubMed

Hinchcliff EM, Bednar EM, Lu KH, Rauh-Hain JA. Disparities in gynecologic cancer genetics evaluation. Gynecol Oncol. 2019;153(1):184–91. https://doi.org/10.1016/j.ygyno.2019.01.024.CrossRefPubMedPubMedCentral

Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014;5:3156. https://doi.org/10.1038/ncomms4156.CrossRefPubMed

du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009;115(6):1234–44. https://doi.org/10.1002/cncr.24149.CrossRefPubMed

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88. https://doi.org/10.1016/s0140-6736(13)62146-7.CrossRefPubMed

Rose PG, Java JJ, Salani R, Geller MA, Secord AA, Tewari KS, et al. Nomogram for predicting individual survival after recurrence of advanced-stage, high-grade ovarian carcinoma. Obstet Gynecol. 2019;133(2):245–54. https://doi.org/10.1097/AOG.0000000000003086.CrossRefPubMedPubMedCentral

Markman M. Maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis Rev. 2015;34(1):11–7. https://doi.org/10.1007/s10555-014-9537-x.CrossRefPubMed

Markman M, Liu PY, Wilczynski S, Monk B, Copeland LJ, Alvarez RD, Jiang C, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. 2003(0732-183X (Print)).

10.

Pecorelli S, Favalli G, Gadducci A, Katsaros D, Panici PB, Carpi A, Scambia G, et al. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1. 2009(1527-7755 (Electronic)).

11.

Hall GD, Brown JM, Coleman RE, Stead M, Metcalf KS, Peel KR, et al. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynaecology group randomised phase III study. Br J Cancer. 2004;91(4):621–6. https://doi.org/10.1038/sj.bjc.6602037.CrossRefPubMedPubMedCentral

12.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

13.

Duncan TJ, Al-Attar A, Rolland P, Scott IV, Deen S, Liu DT, et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies? Clin Cancer Res. 2008;14(10):3030–5. https://doi.org/10.1158/1078-0432.CCR-07-1888.CrossRefPubMed

14.

Yamamoto S, Konishi I, Mandai M, Kuroda H, Komatsu T, Nanbu K, et al. Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels. Br J Cancer. 1997;76(9):1221–7. https://doi.org/10.1038/bjc.1997.537.CrossRefPubMedPubMedCentral

15.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83. https://doi.org/10.1056/NEJMoa1104390.CrossRefPubMed

16.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484–96. https://doi.org/10.1056/NEJMoa1103799.CrossRefPubMed

17.

Oza AM, Cook AD, Pfisterer J, Embleton A, Ledermann JA, Pujade-Lauraine E, et al. Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial. Lancet Oncol. 2015;16(8):928–36. https://doi.org/10.1016/s1470-2045(15)00086-8.CrossRefPubMedPubMedCentral

18.

Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37(26):2317–28. https://doi.org/10.1200/jco.19.01009.CrossRefPubMedPubMedCentral

19.

du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374–82. https://doi.org/10.1200/jco.2014.55.7348.CrossRefPubMed

20.

du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016;17(1):78–89. https://doi.org/10.1016/s1470-2045(15)00366-6.CrossRefPubMed

21.

Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, et al. Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019;155(2):186–91. https://doi.org/10.1016/j.ygyno.2019.08.024.CrossRefPubMed

22.

Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, et al. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer. 2020;146(2):439–48. https://doi.org/10.1002/ijc.32606.CrossRefPubMed

23.

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park S-Y, del Campo JM, et al. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(6):862–76. https://doi.org/10.1016/s1470-2045(19)30178-0.CrossRefPubMed

24.

Collinson F, Hutchinson M, Craven RA, Cairns DA, Zougman A, Wind TC, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res. 2013;19(18):5227–39. https://doi.org/10.1158/1078-0432.CCR-13-0489.CrossRefPubMedPubMedCentral

25.

Backen A, Renehan AG, Clamp AR, Berzuini C, Zhou C, Oza A, et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res. 2014;20(17):4549–58. https://doi.org/10.1158/1078-0432.CCR-13-3248.CrossRefPubMedPubMedCentral

26.

Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434(7035):917–21. https://doi.org/10.1038/nature03445.CrossRefPubMed

27.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366(15):1382–92. https://doi.org/10.1056/NEJMoa1105535.CrossRefPubMed

28.

Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852–61. https://doi.org/10.1016/S1470-2045(14)70228-1.CrossRefPubMed

29.

Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18(9):1274–84. https://doi.org/10.1016/s1470-2045(17)30469-2.CrossRefPubMed

30.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375(22):2154–64. https://doi.org/10.1056/NEJMoa1611310.CrossRefPubMed

31.

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10106):1949–61. https://doi.org/10.1016/s0140-6736(17)32440-6.CrossRefPubMedPubMedCentral

32.

•• Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505. https://doi.org/10.1056/NEJMoa1810858A radomised phase III trial of patients with stage III/IV high grade serous or endometrioid ovarian, fallopian or primary peritoneal cancer, with BRCA1 or BRCA2 mutation, who responded to frontline platinum based chemotherapy to receive olaparib or placebo maitenance. The trial showed a substantial PFS benefit for patients who received olaparib.CrossRefPubMed

33.

•• Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. 811MO Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from SOLO1. Ann Oncol. 2020;31:S613. https://doi.org/10.1016/j.annonc.2020.08.950Published OS data from SOLO1, a phase III radndomised controlled trial of patients with newly diagnosed advanced ovarian cancer with BRCA mutation receiving olaparib or placebo after completion of frontline platinum based chemotherapy. This shows significan OS benefit for patients receiving olaparib.CrossRef

34.

•• Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402. https://doi.org/10.1056/NEJMoa1910962A randomised phase III trial for patients with newly diagnosed advanced high-grade ovarian cancer who responded to platinum-based chemotherapy to receive niraparib or placebo for up to 3 years regardless of a BRCA mutation status. A significant PFS prolongation was seen in all patients, with greatest benefit seen in patients harbouring a BRCA mutation or homologous recombination deficient (HRD) tumours.CrossRefPubMed

35.

•• Ray-Coquard I, Pautier P, Pignata S, Perol D, Gonzalez-Martin A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 2019;381(25):2416–28. https://doi.org/10.1056/NEJMoa1911361Randomised phase III trial for patients with newly diagnosed advanced high grade ovarian cancer responding to fron line platinum-taxane chemotherapy plus bevacisumab to receive oplaparib or placebo. A significant PFS prolongation was seen in the olaparib group for patients with homologous recombination deficiency (HRD).CrossRefPubMed

36.

•• Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403–15. https://doi.org/10.1056/NEJMoa1909707A randomised phase III trial for patients with newly diagnosed stage III/IV high-grade serous ovarian cancer who responded to carboplatin and paclutaxel, regardless of BRCA mutation status. Patients radomised to receive chemotherapy plus placebo followed by placebo maintenance (control), chemotherapy plus veliparib followed by placebo (veliparib combination) or chemotherapy plus veliparib followed by veliparib maintenance (veliparib troughout). significant PFS prolongation was seen across all patients who received veliparib troughout, with the greates benefit seen in patients with BRCA mutation and homologous recombination deficient (HRD) tumours.CrossRefPubMedPubMedCentral

37.

Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15(11):1207–14. https://doi.org/10.1016/S1470-2045(14)70391-2.CrossRefPubMedPubMedCentral

38.

Mirza MR, Mortensen CE, Avall-Lundqvist E, Bjorge L, Berek JS, Herrstedt J, et al. ENGOT-OV24-NSGO/AVANOVA: niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. J Clin Oncol. 2015;33(15_suppl):TPS5607–TPS. https://doi.org/10.1200/jco.2015.33.15_suppl.tps5607.CrossRef

39.

Arora S, Balasubramaniam S, Zhang H, Berman T, Narayan P, Suzman D, et al. FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer. Oncologist. 2020;26:e164–72. https://doi.org/10.1002/onco.13551.CrossRefPubMedPubMedCentral

40.

Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer. 2020;30(7):903–15. https://doi.org/10.1136/ijgc-2020-001288.CrossRefPubMedPubMedCentral

41.

LaFargue CJ, Dal Molin GZ, Sood AK, Coleman RL. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol. 2019;20(1):e15–28. https://doi.org/10.1016/S1470-2045(18)30786-1.CrossRefPubMedPubMedCentral

42.

Sabbatini P, Harter P, Scambia G, Sehouli J, Meier W, Wimberger P, et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA study. J Clin Oncol. 2013;31(12):1554–61. https://doi.org/10.1200/jco.2012.46.4057.CrossRefPubMedPubMedCentral

43.

Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203–13. https://doi.org/10.1056/NEJMoa020177.CrossRefPubMed

44.

Hwang WT, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–8. https://doi.org/10.1016/j.ygyno.2011.09.039.CrossRefPubMed

45.

Sharma P, Allison JP. The future of immune checkpoint therapy. Science. 2015;348(6230):56–61. https://doi.org/10.1126/science.aaa8172.CrossRefPubMed

46.

Matulonis UA, Shapira-Frommer R, Santin AD, Lisyanskaya AS, Pignata S, Vergote I, et al. Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019;30(7):1080–7. https://doi.org/10.1093/annonc/mdz135.CrossRefPubMed

47.

Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-pd-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2015;33(34):4015–22. https://doi.org/10.1200/JCO.2015.62.3397.CrossRefPubMed

48.

Liu JF, Gordon M, Veneris J, Braiteh F, Balmanoukian A, Eder JP, et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers. Gynecol Oncol. 2019;154(2):314–22. https://doi.org/10.1016/j.ygyno.2019.05.021.CrossRefPubMed

49.

Ledermann JA, Colombo N, Oza AM, Fujiwara K, Birrer MJ, Randall LM, et al. Avelumab in combination with and/or following chemotherapy vs chemotherapy alone in patients with previously untreated epithelial ovarian cancer: results from the phase 3 javelin ovarian 100 trial. Gynecol Oncol. 2020;159:13–4. https://doi.org/10.1016/j.ygyno.2020.06.025.CrossRef

50.

Eskander RN, Ledermann JA, Birrer MJ, Fujiwara K, Gaillard S, Richardson GE, et al. JAVELIN ovarian PARP 100 study design: phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer. J Clin Oncol. 2019;37(8_suppl):TPS9–TPS. https://doi.org/10.1200/JCO.2019.37.8_suppl.TPS9.CrossRef

51.

Moore KN, Bookman M, Sehouli J, Miller A, Anderson C, Scambia G, et al. LBA31 Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase III trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC). Ann Oncol. 2020;31:S1161–S2. https://doi.org/10.1016/j.annonc.2020.08.2261.CrossRef

52.

Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15. https://doi.org/10.1038/nature10166.CrossRef

53.

Strickland KC, Howitt BE, Shukla SA, Rodig S, Ritterhouse LL, Liu JF, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016;7(12):13587–98. https://doi.org/10.18632/oncotarget.7277.CrossRefPubMedPubMedCentral

54.

Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, et al. BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer. Oncotarget. 2018;9(25):17501–11. https://doi.org/10.18632/oncotarget.24770.CrossRefPubMedPubMedCentral

55.

Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1–10. https://doi.org/10.1016/j.immuni.2013.07.012.CrossRefPubMed

56.

Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21. https://doi.org/10.1038/nature12477.CrossRefPubMedPubMedCentral

57.

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018;362(6411). https://doi.org/10.1126/science.aar3593.

58.

Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013;45(10):1127–33. https://doi.org/10.1038/ng.2762.CrossRefPubMedPubMedCentral

59.

McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259–71 e11. https://doi.org/10.1016/j.cell.2017.10.001.CrossRefPubMedPubMedCentral

60.

Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567(7749):479–85. https://doi.org/10.1038/s41586-019-1032-7.CrossRefPubMedPubMedCentral

61.

Yuan X, Zhang J, Li D, Mao Y, Mo F, Du W, et al. Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis. Gynecol Oncol. 2017;147(1):181–7. https://doi.org/10.1016/j.ygyno.2017.07.007.CrossRefPubMed

62.

Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27(4):462–72. https://doi.org/10.1016/j.ccell.2015.02.015.CrossRefPubMedPubMedCentral

63.

Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 2016;6(8):827–37. https://doi.org/10.1158/2159-8290.Cd-15-1545.CrossRefPubMedPubMedCentral

64.

Wong YNS, Joshi K, Khetrapal P, Ismail M, Reading JL, Sunderland MW, et al. Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. J Exp Med. 2018;215(11):2748–59. https://doi.org/10.1084/jem.20181003.CrossRefPubMedPubMedCentral

65.

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71. https://doi.org/10.1038/nature13954.CrossRefPubMedPubMedCentral

66.

Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7. https://doi.org/10.1038/nature14011.CrossRefPubMedPubMedCentral

67.

Shen Z, Luo H, Li S, Sheng B, Zhao M, Zhu H, et al. Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis. Oncotarget. 2017;8(37):62400–13. https://doi.org/10.18632/oncotarget.18253.

68.

Sieh W, Köbel M, Longacre TA, Bowtell DD. deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013;14(9):853–62. https://doi.org/10.1016/s1470-2045(13)70253-5.CrossRefPubMedPubMedCentral

69.

Llaurado Fernandez M, Dawson A, Kim H, Lam N, Russell H, Bruce M, et al. Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. Gynecol Oncol. 2020;157(1):12–20. https://doi.org/10.1016/j.ygyno.2019.11.029.CrossRefPubMed

70.

Gershenson DM, Bodurka DC, Coleman RL, Lu KH, Malpica A, Sun CC. Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. J Clin Oncol. 2017;35(10):1103–11. https://doi.org/10.1200/JCO.2016.71.0632.CrossRefPubMedPubMedCentral

Title: Frontline Maintenance Treatment for Ovarian Cancer
Authors: Osnat Elyashiv
Yien Ning Sophia Wong
Jonathan A. Ledermann
Publication date: 01-08-2021
Publisher: Springer US
Keywords: Ovarian Cancer
Ovarian Cancer
Targeted Therapy
Bevacizumab
Checkpoint Inhibitors
Cytostatic Therapy
Peritoneal Cancer
Peritoneal Carcinomatosis
Published in: Current Oncology Reports / Issue 8/2021
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI: https://doi.org/10.1007/s11912-021-01088-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 8/2021

The Microbiome and Gynecologic Cancer: Current Evidence and Future Opportunities

Correction to: Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review

Review of New-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review

The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic

Management of Intractable Symptoms in Oncologic Care

Keynote webinar | Spotlight on antibody–drug conjugates in cancer